Methods and compositions for the treatment of Hodgkin's disease

Details Methods and compositions for the treatment of Hodgkin's disease Methods and compositions for the treatment of Hodgkin's disease

1989-11-20

1992-11-24

Nucker, Christine

Drug, bio-affecting and body treating compositions

Lymphokine

5303919, 5303887, 53038873, 53038875, A61K 3944, C07K 1702, C07K 1528

Patent

active

051659239

ABSTRACT:
Disclosed are methods and compositions for the treatment of Hodgkin's disease and processes involving Hodgkin's disease cells or Reed-Sternberg cells, through specific elimination of Hodgkin's disease cells through the application of immunotoxin technology. The compositions of the invention include toxin conjugates composed of a Hodgkin's disease cell binding ligand conjugated to a toxin A chain moiety such as ricin A chain or deglycosylated ricin A chain, by means of a cross-linker or other conjugation which includes a disulfide bond. In preferred aspects of the invention, therapeutic amounts of conjugates composed of a CD-30 or IRac antibody or fragment thereof conjugated to deglycosylated A chain by means of an SMPT linker is administered to a Hodgkin's disease patient so as to specifically eliminate Hodgkin's disease cells without exerting significant toxicity against non-tumor cells. Also disclosed are particular hybridomas and monoclonal antibodies, and associated methodology, which may be employed, e.g., in the preparation of these immunotoxins as well as other uses such as diagnostic applications.

REFERENCES:
Engert et al. (1990a) Cancer Res. 50: 84-88.
Engert et al. (1990b) Cancer Res. 50: 2929-2935.
Fulton et al. (1988a) Cancer Res. 48(9): 2618-25.
Fulton et al. (1988b) Cancer Res. 48: 2626-31.
Ghetia (1988) Cancer Res. 48(9): 2610-17.
Thorpe et al. (1987) Cancer Res. 47: 5924-31.
Thorpe et al. (1988) Cancer Res. 48: 6396-6403.
Hsu et al., "Identification of an M.sub.r 70,000 Antigen Asssociated with Reed-Sternberg Cells and Interdigitating Reticulum Cells," Cancer Research, 50: 1-8, (1990).
Schwarting et al., "BER-H2: A New Anti-K-1 (CD30) Monoclonal Antibody Directed at Formol-Resistant Epitope," Blood, 74(5): 1678-1689, (1989).
Gause et al., "Soluble Hodgkin-Associated CD30 Antigen Is a Specific Serum Tumor Marker in Hodkgin's Disease: Correlation with Soluble IL-2-Receptor Levels," Blut, 59, 3, 211A, 297 (1989).
Engert et al., "Immunotoxins for the Treatment of Hodgkin's Disease", Blut, 59, 3, 212A, 297 (1989).
Pfreundschuh et al., "Hodkgin and Reed-Sternberg Cell Associated Monoclonal Antibodies HRS-1 and HRS-2 React with Activated Cells of Lymphoid and Monocytoid Origin," Anticancer Research, 8: 217-224, (1988).
Vitetta et al., "Redesigning Nature's Poisons to Create Anti-Tumor Reagents," Science, 238: 1098-1104 (1987).
Hsu et al., "Effect of Monoclonal Antibodies Anti-2H9, Anti-IRac, and Anti-HeFi-1 on the Surface of Antigens of Reed-Sternberg Cells,: JNCI 79(5)", 1091-1099, (1987).
Kronke et al., "Adult T Cell Leukemia: A Potential Target for Ricin A Chain Immunotoxins," Blood, 65(6):1416-1421, (1985).
Stein et al., "The Expression of the Hodgkin's Disease Associated Antigen Ki-1 Reactive and Neoplastic Lymphoid Tissue: Evidence that Reed-Sternberg Cells and Histiocytic Malignancies are Derived from Activated Lymphoid Cells," Blood, 66(4):848-858, (1985).
Depper et al., "Augmented T Cell Growth Factor Receptor Expression in HTLV-1 Infected Human Leukemic T Cells," The Journal of Immunology 133(4):1691-1695, (1984).
Schwab et al., "Production of a Monoclonal Antibody Specific for Hodgkin and Sternberg-Reed Cells of Hodgkin's Disease and a Subset of Normal Lymphoid Cells," Nature, 299: 65-67, (1982).
Schwarting et al., Leucocyte typing, 3: 574-575, 1987.
Diehl et al., Cancer Surveys, 4(2):399-419, 1985.
Bjorn et al., Cancer Research, 45:1214-1221, 1985.
Press et al., J. Immunol., 141:4410-4417, 1988.
May et al., The J. Immunol., 144:3637-42, 1990.

Affiliated with

Also associated with

Rating

Methods and compositions for the treatment of Hodgkin's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for the treatment of Hodgkin's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of Hodgkin's disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-920333